메뉴 건너뛰기




Volumn 77, Issue 1, 2010, Pages 20-26

New treatments for myeloma

Author keywords

Bortezomib; Lenalidomide; Thalidomide

Indexed keywords

BORTEZOMIB; CAELIX; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; UNCLASSIFIED DRUG;

EID: 73449084761     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2009.10.009     Document Type: Short Survey
Times cited : (3)

References (60)
  • 1
    • 41949130070 scopus 로고    scopus 로고
    • Improved survival in multiple myeloma and the impact of novel therapies
    • Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111 (2008) 2516-2520
    • (2008) Blood , vol.111 , pp. 2516-2520
    • Kumar, S.K.1    Rajkumar, S.V.2    Dispenzieri, A.3
  • 2
    • 34848833957 scopus 로고    scopus 로고
    • Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
    • Facon T., Mary J.Y., Hulin C., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370 (2007) 1209-1218
    • (2007) Lancet , vol.370 , pp. 1209-1218
    • Facon, T.1    Mary, J.Y.2    Hulin, C.3
  • 3
    • 50449086728 scopus 로고    scopus 로고
    • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    • San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359 (2008) 906-917
    • (2008) N Engl J Med , vol.359 , pp. 906-917
    • San Miguel, J.F.1    Schlag, R.2    Khuageva, N.K.3
  • 4
    • 0038509089 scopus 로고    scopus 로고
    • Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group
    • International Myeloma Working Group
    • International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
    • (2003) Br J Haematol , vol.121 , pp. 749-757
  • 5
    • 20644460600 scopus 로고    scopus 로고
    • International staging system for multiple myeloma
    • Greipp P.R., San Miguel J., Durie B.G.M., et al. International staging system for multiple myeloma. J Clin Oncol 23 (2005) 3412-3420
    • (2005) J Clin Oncol , vol.23 , pp. 3412-3420
    • Greipp, P.R.1    San Miguel, J.2    Durie, B.G.M.3
  • 6
    • 33847378314 scopus 로고    scopus 로고
    • Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
    • Avet-Loiseau H., Attal M., Moreau P., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 109 (2007) 3489-3495
    • (2007) Blood , vol.109 , pp. 3489-3495
    • Avet-Loiseau, H.1    Attal, M.2    Moreau, P.3
  • 7
    • 8944220233 scopus 로고    scopus 로고
    • A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francophone du Myélome
    • Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francophone du Myélome. N Engl J Med 335 (1996) 91-97
    • (1996) N Engl J Med , vol.335 , pp. 91-97
    • Attal, M.1    Harousseau, J.L.2    Stoppa, A.M.3
  • 8
    • 20444433230 scopus 로고    scopus 로고
    • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
    • Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
    • (2005) N Engl J Med , vol.352 , pp. 2487-2498
    • Richardson, P.G.1    Sonneveld, P.2    Schuster, M.W.3
  • 9
    • 36349010285 scopus 로고    scopus 로고
    • Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
    • Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357 (2007) 2133-2142
    • (2007) N Engl J Med , vol.357 , pp. 2133-2142
    • Weber, D.M.1    Chen, C.2    Niesvizky, R.3
  • 10
    • 36349023319 scopus 로고    scopus 로고
    • Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    • Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357 (2007) 2123-2132
    • (2007) N Engl J Med , vol.357 , pp. 2123-2132
    • Dimopoulos, M.1    Spencer, A.2    Attal, M.3
  • 11
    • 84988241358 scopus 로고    scopus 로고
    • International uniform response criteria for multiple myeloma
    • Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 20 (2006) 1467-1473
    • (2006) Leukemia , vol.20 , pp. 1467-1473
    • Durie, B.G.1    Harousseau, J.L.2    Miguel, J.S.3
  • 12
    • 0028775544 scopus 로고
    • The treatment of multiple myeloma
    • Alexanian R., and Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 330 (1994) 484-489
    • (1994) N Engl J Med , vol.330 , pp. 484-489
    • Alexanian, R.1    Dimopoulos, M.2
  • 13
    • 0344076348 scopus 로고    scopus 로고
    • Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials
    • Myeloma Trialists' Collaborative Group
    • Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16 (1998) 3832-3842
    • (1998) J Clin Oncol , vol.16 , pp. 3832-3842
  • 14
    • 32644438680 scopus 로고    scopus 로고
    • Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
    • Facon T., Mary J.Y., Pégourié B., et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107 (2006) 1292-1298
    • (2006) Blood , vol.107 , pp. 1292-1298
    • Facon, T.1    Mary, J.Y.2    Pégourié, B.3
  • 15
    • 8644260170 scopus 로고    scopus 로고
    • Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: results of a randomized controlled trial
    • Palumbo A., Bringhen S., Petrucci M.T., et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: results of a randomized controlled trial. Blood 104 (2004) 3052-3057
    • (2004) Blood , vol.104 , pp. 3052-3057
    • Palumbo, A.1    Bringhen, S.2    Petrucci, M.T.3
  • 16
    • 41949114641 scopus 로고    scopus 로고
    • Recent major improvement in long-term survival of younger patients with multiple myeloma
    • Brenner H., Gondos A., and Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111 (2008) 2521-2526
    • (2008) Blood , vol.111 , pp. 2521-2526
    • Brenner, H.1    Gondos, A.2    Pulte, D.3
  • 17
    • 33644843725 scopus 로고    scopus 로고
    • Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
    • Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831
    • (2006) Lancet , vol.367 , pp. 825-831
    • Palumbo, A.1    Bringhen, S.2    Caravita, T.3
  • 18
    • 54049135250 scopus 로고    scopus 로고
    • Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
    • Palumbo A., Bringhen S., Liberati A.M., et al. Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112 (2008) 3107-3114
    • (2008) Blood , vol.112 , pp. 3107-3114
    • Palumbo, A.1    Bringhen, S.2    Liberati, A.M.3
  • 19
    • 68949137225 scopus 로고    scopus 로고
    • Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial
    • Hulin C., Facon T., Rodon P., et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 27 (2009) 3664-3670
    • (2009) J Clin Oncol , vol.27 , pp. 3664-3670
    • Hulin, C.1    Facon, T.2    Rodon, P.3
  • 20
    • 60849131974 scopus 로고    scopus 로고
    • Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch cooperative group HOVON 49 study
    • [abstract]
    • Wijermans P., Schaafsma M., van Norden Y., et al. Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch cooperative group HOVON 49 study. Blood 112 (2008) 649 [abstract]
    • (2008) Blood , vol.112 , pp. 649
    • Wijermans, P.1    Schaafsma, M.2    van Norden, Y.3
  • 21
    • 43249097561 scopus 로고    scopus 로고
    • Thalidomide for treatment of multiple myeloma: ten years later
    • Palumbo A., Facon T., Sonneveld P., et al. Thalidomide for treatment of multiple myeloma: ten years later. Blood 111 (2008) 3968-3977
    • (2008) Blood , vol.111 , pp. 3968-3977
    • Palumbo, A.1    Facon, T.2    Sonneveld, P.3
  • 22
    • 33748287079 scopus 로고    scopus 로고
    • Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
    • Mateos M.V., Hernandez J.M., Hernandez M.T., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108 (2006) 2165-2172
    • (2006) Blood , vol.108 , pp. 2165-2172
    • Mateos, M.V.1    Hernandez, J.M.2    Hernandez, M.T.3
  • 23
    • 42149176608 scopus 로고    scopus 로고
    • Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
    • Mateos M.V., Hernandez J.M., Hernandez M.T., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 93 (2008) 560-565
    • (2008) Haematologica , vol.93 , pp. 560-565
    • Mateos, M.V.1    Hernandez, J.M.2    Hernandez, M.T.3
  • 24
    • 70450275124 scopus 로고    scopus 로고
    • Updated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma
    • [abstract]
    • San Miguel J.F., Schlag R., Khuageva N.K., et al. Updated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma. Blood 112 (2008) 650 [abstract]
    • (2008) Blood , vol.112 , pp. 650
    • San Miguel, J.F.1    Schlag, R.2    Khuageva, N.K.3
  • 25
    • 35348923502 scopus 로고    scopus 로고
    • Melphalan, prednisone and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMENA - Italian Multiple Myeloma Network
    • Palumbo A., Falco P., Corradini P., et al. Melphalan, prednisone and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMENA - Italian Multiple Myeloma Network. J Clin Oncol 25 (2007) 4459-4465
    • (2007) J Clin Oncol , vol.25 , pp. 4459-4465
    • Palumbo, A.1    Falco, P.2    Corradini, P.3
  • 26
    • 58149376363 scopus 로고    scopus 로고
    • Thalidomide combinations improve response rates; Results from the MRC IX study
    • [abstract]
    • Morgan G.J., Davies F.E., Owen R.G., et al. Thalidomide combinations improve response rates; Results from the MRC IX study. Blood 110 (2007) 3593 [abstract]
    • (2007) Blood , vol.110 , pp. 3593
    • Morgan, G.J.1    Davies, F.E.2    Owen, R.G.3
  • 27
    • 33644831033 scopus 로고    scopus 로고
    • Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group
    • Rajkumar S.V., Blood E., Vesole D., et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24 (2006) 431-436
    • (2006) J Clin Oncol , vol.24 , pp. 431-436
    • Rajkumar, S.V.1    Blood, E.2    Vesole, D.3
  • 28
    • 51049103084 scopus 로고    scopus 로고
    • Thalidomide-dexamethasone vs. melphalan-prednisone as first line treatment and thalidomide-interferon vs. interferon maintenance therapy in elderly patients with multiple myeloma
    • [abstract]
    • Ludwig H., Tothova E., Hajek R., et al. Thalidomide-dexamethasone vs. melphalan-prednisone as first line treatment and thalidomide-interferon vs. interferon maintenance therapy in elderly patients with multiple myeloma. Blood 110 (2007) 529 [abstract]
    • (2007) Blood , vol.110 , pp. 529
    • Ludwig, H.1    Tothova, E.2    Hajek, R.3
  • 29
    • 27744492561 scopus 로고    scopus 로고
    • Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
    • Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
    • (2005) Blood , vol.106 , pp. 4050-4053
    • Rajkumar, S.V.1    Hayman, S.R.2    Lacy, M.Q.3
  • 30
    • 34848824393 scopus 로고    scopus 로고
    • Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
    • Lacy M.Q., Gertz M.A., Dispenzieri A., et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 82 (2007) 1179-1184
    • (2007) Mayo Clin Proc , vol.82 , pp. 1179-1184
    • Lacy, M.Q.1    Gertz, M.A.2    Dispenzieri, A.3
  • 31
    • 41349095820 scopus 로고    scopus 로고
    • A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group
    • [abstract]
    • Rajkumar S.V., Jacobus S., Callander N., et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 110 (2007) 74 [abstract]
    • (2007) Blood , vol.110 , pp. 74
    • Rajkumar, S.V.1    Jacobus, S.2    Callander, N.3
  • 32
    • 64749086411 scopus 로고    scopus 로고
    • Bortezomib (Velcade)-melphalan-prednisone (VMP) versus velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: Which is the best partner for Velcade? An alkylating or an immunomodulator agent?
    • [abstract]
    • Mateos M.V., Oriol A., Martinez J., et al. Bortezomib (Velcade)-melphalan-prednisone (VMP) versus velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: Which is the best partner for Velcade? An alkylating or an immunomodulator agent?. Blood 112 (2008) 651 [abstract]
    • (2008) Blood , vol.112 , pp. 651
    • Mateos, M.V.1    Oriol, A.2    Martinez, J.3
  • 33
    • 70350700998 scopus 로고    scopus 로고
    • A prospective, randomized, phase III study of bortezomib. Melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed multiple myeloma patients
    • [abstract]
    • Palumbo A., Bringhen S., Rossi D., et al. A prospective, randomized, phase III study of bortezomib. Melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed multiple myeloma patients. Blood 112 (2008) 652 [abstract]
    • (2008) Blood , vol.112 , pp. 652
    • Palumbo, A.1    Bringhen, S.2    Rossi, D.3
  • 34
    • 33846274225 scopus 로고    scopus 로고
    • High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
    • Koreth J., Cutler C.S., Djulbegovic B., et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 1 (2007) 183-196
    • (2007) Biol Blood Marrow Transplant , vol.1 , pp. 183-196
    • Koreth, J.1    Cutler, C.S.2    Djulbegovic, B.3
  • 35
    • 44649149612 scopus 로고    scopus 로고
    • ®-Dexamethasone versus VAD as induction treatment prior to ASCT in newly diagnosed multiple myeloma. Updated results of the IFM2005/01 trial
    • [abstract]
    • ®-Dexamethasone versus VAD as induction treatment prior to ASCT in newly diagnosed multiple myeloma. Updated results of the IFM2005/01 trial. Blood 110 (2007) 450 [abstract]
    • (2007) Blood , vol.110 , pp. 450
    • Harousseau, J.L.1    Mathiot, C.2    Attal, M.3
  • 36
    • 64749108582 scopus 로고    scopus 로고
    • First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan in patients with newly diagnosed multiple myeloma
    • [abstract]
    • Sonneveld P., van des Holt B., Schmidt-Wolf I.G.H., et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan in patients with newly diagnosed multiple myeloma. Blood 112 (2008) 653 [abstract]
    • (2008) Blood , vol.112 , pp. 653
    • Sonneveld, P.1    van des Holt, B.2    Schmidt-Wolf, I.G.H.3
  • 37
    • 22044452126 scopus 로고    scopus 로고
    • Superiority of thalidomide and dexamethasone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
    • Cavo M., Zamagni E., Tosi P., et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 (2005) 35-39
    • (2005) Blood , vol.106 , pp. 35-39
    • Cavo, M.1    Zamagni, E.2    Tosi, P.3
  • 38
    • 47649091923 scopus 로고    scopus 로고
    • Lenalidomide, bortezomib, and dexamethasone as front-line therapy for patients with multiple myeloma: preliminary results of a phase 1/2 study
    • [abstract]
    • Richardson P., Jagannath S., Raje N., et al. Lenalidomide, bortezomib, and dexamethasone as front-line therapy for patients with multiple myeloma: preliminary results of a phase 1/2 study. Blood 110 (2007) 187 [abstract]
    • (2007) Blood , vol.110 , pp. 187
    • Richardson, P.1    Jagannath, S.2    Raje, N.3
  • 39
    • 64749089107 scopus 로고    scopus 로고
    • Superior complete response rate and progression free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma
    • [abstract]
    • Cavo M., Tacchetti P., Patriarca F., et al. Superior complete response rate and progression free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma. Blood 112 (2008) 158 [abstract]
    • (2008) Blood , vol.112 , pp. 158
    • Cavo, M.1    Tacchetti, P.2    Patriarca, F.3
  • 40
    • 0036464598 scopus 로고    scopus 로고
    • 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome randomized trial
    • 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome randomized trial. Blood 99 (2002) 731-735
    • (2002) Blood , vol.99 , pp. 731-735
    • Moreau, P.1    Facon, T.2    Attal, M.3
  • 41
    • 34347260711 scopus 로고    scopus 로고
    • Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study
    • Cavo M., Tosi P., Zamagni E., et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 25 (2007) 2434-2441
    • (2007) J Clin Oncol , vol.25 , pp. 2434-2441
    • Cavo, M.1    Tosi, P.2    Zamagni, E.3
  • 42
    • 70450266619 scopus 로고    scopus 로고
    • Bortezomib and high dose melphalan as conditioning regimen before autologous stem cell transplantation for de novo multiple myeloma: final results of the IFM phase II study VEL/MEL
    • [abstract]
    • Roussel M., Huynh A., Moreau P., et al. Bortezomib and high dose melphalan as conditioning regimen before autologous stem cell transplantation for de novo multiple myeloma: final results of the IFM phase II study VEL/MEL. Blood 112 (2008) 160 [abstract]
    • (2008) Blood , vol.112 , pp. 160
    • Roussel, M.1    Huynh, A.2    Moreau, P.3
  • 43
    • 33751164196 scopus 로고    scopus 로고
    • Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
    • Attal M., Harousseau J.L., Leyvraz S., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108 (2006) 3289-3294
    • (2006) Blood , vol.108 , pp. 3289-3294
    • Attal, M.1    Harousseau, J.L.2    Leyvraz, S.3
  • 44
    • 41349095233 scopus 로고    scopus 로고
    • Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial
    • Abdelkefi A., Ladeb S., Torjman L., et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 111 (2008) 1805-1810
    • (2008) Blood , vol.111 , pp. 1805-1810
    • Abdelkefi, A.1    Ladeb, S.2    Torjman, L.3
  • 45
    • 0032748385 scopus 로고    scopus 로고
    • Antitumor activity of thalidomide in refractory multiple myeloma
    • Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571
    • (1999) N Engl J Med , vol.341 , pp. 1565-1571
    • Singhal, S.1    Mehta, J.2    Desikan, R.3
  • 46
    • 0037973279 scopus 로고    scopus 로고
    • A phase 2 study of bortezomib in relapsed, refractory myeloma
    • Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
    • (2003) N Engl J Med , vol.348 , pp. 2609-2617
    • Richardson, P.G.1    Barlogie, B.2    Berenson, J.3
  • 47
    • 57349171505 scopus 로고    scopus 로고
    • Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma
    • Moreau P., Coiteux V., Hulin C., et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 93 (2008) 1908-1911
    • (2008) Haematologica , vol.93 , pp. 1908-1911
    • Moreau, P.1    Coiteux, V.2    Hulin, C.3
  • 48
    • 27644510071 scopus 로고    scopus 로고
    • Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
    • Berenson J.R., Jagannath S., Barlogie B., et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 104 (2005) 2141-2148
    • (2005) Cancer , vol.104 , pp. 2141-2148
    • Berenson, J.R.1    Jagannath, S.2    Barlogie, B.3
  • 49
    • 20044381304 scopus 로고    scopus 로고
    • Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function
    • Jagannath S., Barlogie B., Berenson J.R., et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 103 (2005) 1195-1200
    • (2005) Cancer , vol.103 , pp. 1195-1200
    • Jagannath, S.1    Barlogie, B.2    Berenson, J.R.3
  • 50
    • 27644476353 scopus 로고    scopus 로고
    • Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
    • Richardson P.G., Barlogie B., Berenson J., et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 106 (2005) 2977-2981
    • (2005) Blood , vol.106 , pp. 2977-2981
    • Richardson, P.G.1    Barlogie, B.2    Berenson, J.3
  • 51
    • 34548539381 scopus 로고    scopus 로고
    • Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression
    • Orlowski R.Z., Nagler A., Sonneveld P., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25 (2007) 3892-3901
    • (2007) J Clin Oncol , vol.25 , pp. 3892-3901
    • Orlowski, R.Z.1    Nagler, A.2    Sonneveld, P.3
  • 52
    • 58149384555 scopus 로고    scopus 로고
    • Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
    • Wang M., Dimopoulos M.A., Chen C., et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112 (2008) 4445-4451
    • (2008) Blood , vol.112 , pp. 4445-4451
    • Wang, M.1    Dimopoulos, M.A.2    Chen, C.3
  • 53
    • 66149109580 scopus 로고    scopus 로고
    • Lenalidomide (Revlimid (R)), adriamycin and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
    • Knop S., Gerecke C., Liebisch P., et al. Lenalidomide (Revlimid (R)), adriamycin and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 113 (2009) 4137-4143
    • (2009) Blood , vol.113 , pp. 4137-4143
    • Knop, S.1    Gerecke, C.2    Liebisch, P.3
  • 54
    • 33947575994 scopus 로고    scopus 로고
    • Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma
    • Palumbo A., Ambrosini M.T., Benevolo G., et al. Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood 109 (2007) 2767-2772
    • (2007) Blood , vol.109 , pp. 2767-2772
    • Palumbo, A.1    Ambrosini, M.T.2    Benevolo, G.3
  • 56
    • 44449139385 scopus 로고    scopus 로고
    • Bisphosphonates et traitements innovants de l'ostéolyse tumorale
    • Debiais F. Bisphosphonates et traitements innovants de l'ostéolyse tumorale. Rev Rhum 75 (2008) 511-522
    • (2008) Rev Rhum , vol.75 , pp. 511-522
    • Debiais, F.1
  • 57
    • 58949104001 scopus 로고    scopus 로고
    • Reduction of osteonecrosis of the jaw after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
    • Dimopoulos M.A., Kastritis E., Bamia C., et al. Reduction of osteonecrosis of the jaw after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20 (2009) 117-120
    • (2009) Ann Oncol , vol.20 , pp. 117-120
    • Dimopoulos, M.A.1    Kastritis, E.2    Bamia, C.3
  • 59
    • 34548128339 scopus 로고    scopus 로고
    • The effect of novel antimyeloma agents on bone metabolism of patients with multiple myeloma
    • Terpos E., Dimopoulos M.A., and Sezer O. The effect of novel antimyeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 21 (2007) 1875-1884
    • (2007) Leukemia , vol.21 , pp. 1875-1884
    • Terpos, E.1    Dimopoulos, M.A.2    Sezer, O.3
  • 60
    • 33644760436 scopus 로고    scopus 로고
    • A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bones metastases from breast cancer
    • Body J.J., Facon T., Coleman R.E., et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bones metastases from breast cancer. Clin Cancer Res 12 (2006) 1221-1228
    • (2006) Clin Cancer Res , vol.12 , pp. 1221-1228
    • Body, J.J.1    Facon, T.2    Coleman, R.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.